DaVita Inc. (NYSE:DVA) Stock Has Consensus Target Price of $233.43

DaVita Inc. (NYSE:DVA) has received an average rating of “Moderate Buy” from the seven analysts that are currently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $233.43.

DVA has been the subject of a number of analyst reports. Barclays increased their price objective on DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 5th. Zacks Research cut shares of DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Raymond James Financial set a $220.00 price target on shares of DaVita in a report on Friday, August 7th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $265.00 price target on shares of DaVita in a report on Wednesday, August 5th. Finally, Truist Financial dropped their target price on shares of DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a report on Friday, August 7th.

DaVita Price Performance

Shares of NYSE DVA traded up $0.27 during trading on Tuesday, reaching $182.05. 31,048 shares of the stock traded hands, compared to its average volume of 893,150. The company has a 50-day moving average of $181.31 and a 200-day moving average of $189.98. The stock has a market capitalization of $11.61 billion, a P/E ratio of 14.88, a price-to-earnings-growth ratio of 0.46 and a beta of 0.80. DaVita has a 52-week low of $101.00 and a 52-week high of $247.49.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The business had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.50 billion. During the same period in the previous year, the business earned $2.95 EPS. DaVita’s revenue was up 5.2% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Analysts expect that DaVita will post 14.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Fifth Third Bancorp grew its position in shares of DaVita by 831.4% in the 1st quarter. Fifth Third Bancorp now owns 38,411 shares of the company’s stock worth $5,903,000 after buying an additional 34,287 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in shares of DaVita by 30.5% during the second quarter. Assenagon Asset Management S.A. now owns 44,783 shares of the company’s stock valued at $9,963,000 after buying an additional 10,477 shares during the period. Wellington Management Group LLP raised its holdings in shares of DaVita by 305.1% during the second quarter. Wellington Management Group LLP now owns 9,610 shares of the company’s stock valued at $2,138,000 after acquiring an additional 7,238 shares in the last quarter. Berkshire Hathaway Inc bought a new position in shares of DaVita during the second quarter valued at approximately $6,425,269,000. Finally, SG Americas Securities LLC lifted its stake in DaVita by 27.4% in the first quarter. SG Americas Securities LLC now owns 212,293 shares of the company’s stock worth $32,627,000 after acquiring an additional 45,609 shares during the period. Institutional investors own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc is a healthcare company focused on kidney care and renal disease management. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with end-stage kidney disease, including hemodialysis and peritoneal dialysis, as well as home dialysis support.

The company also operates hospital-based dialysis programs and offers clinical, administrative and care-coordination services intended to support patients across the kidney-care journey.